Related Experiment Video

Updated: Jul 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death

Ali A Sovari1, Norishige Morita, James N Weiss

  • 1Translational Arrhythmia Research Laboratory, Cardiovascular Research Laboratory, Division of Cardiology Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, United States. asovari@mednet.ucla.edu

Medical Hypotheses
|May 2, 2008
PubMed

Insights

Monitoring serum levels of transforming growth factor-beta1 (TGF-beta1) may help identify individuals at high risk for sudden cardiac death. This cost-effective approach could aid in preventing fatal ventricular arrhythmias like ventricular tachycardia and ventricular fibrillation.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathophysiology

Background:

  • Sudden cardiac death (SCD) causes 7 million deaths globally each year, primarily due to ventricular tachycardia (VT) and ventricular fibrillation (VF) in patients with structural heart disease.
  • Current risk stratification tools for SCD are often expensive, highlighting the need for cost-effective alternatives.
  • Myocardial fibrosis is a common finding in cardiac diseases linked to increased risk of VT/VF and SCD.

Purpose of the Study:

  • To propose transforming growth factor-beta1 (TGF-beta1) as a potential serum biomarker for risk stratification of SCD.
  • To investigate the association between serum TGF-beta1 levels and myocardial fibrosis in cardiac conditions.

Main Methods:

  • This is a hypothesis-driven study.
  • The study proposes monitoring serum TGF-beta1 levels as a risk stratification tool.
  • Correlational analysis between serum TGF-beta1 and myocardial fibrosis is suggested.

Main Results:

  • Increased myocardial fibrosis is linked to a higher risk of VT and VF.
  • Serum TGF-beta1 levels are positively correlated with myocardial fibrosis in cardiac conditions.
  • This suggests TGF-beta1 may play a role in promoting fibrosis and subsequent arrhythmias.

Conclusions:

  • Monitoring serum TGF-beta1 levels may offer a cost-effective method for identifying patients at high risk of SCD.
  • This approach could lead to timely interventions and improved prevention of fatal arrhythmias.
  • Further clinical validation is warranted to confirm TGF-beta1's utility in SCD risk stratification.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...